The respective proportions of persons who developed a confirmed @ % or greater eGFR decline from baseline by @ and @ months was @ % and @ % for TDF and @ % and @ % for FTC-TDF , and these frequencies were not statistically different from the confirmed decline in the placebo group ( @ % and @ % by @ and @ months , respectively ) .